FOSUN INTL(HK:00656) Xin Lang Zheng Quan·2025-08-29 05:57Core Viewpoint - Fosun International is committed to increasing investments in the biopharmaceutical sector, focusing on leveraging its strengths to capture global market opportunities [1] Group 1: Business Strategy - Fosun has achieved significant breakthroughs in multiple business segments in the first half of the year, particularly in the biopharmaceutical sector, and aims to drive growth through technological innovation [1] - The company has a pipeline of innovative drugs with a potential global market size of $5 billion to $10 billion, including products from its subsidiaries such as Fosun Pharma and its CAR-T technology platform [1][2] Group 2: Innovation and R&D - Fosun emphasizes the importance of both licensing in and licensing out for innovative drugs, aiming to develop products into globally competitive offerings rather than rushing to license them out [2] - The company believes that cancer treatment will not rely on a single method but will involve a combination of drugs, devices, and multi-molecular therapies, positioning itself uniquely in this area [2] Group 3: Long-term Vision - Fosun's leadership highlights that building a competitive enterprise requires a long-term commitment, as seen in the 15-year journey of its subsidiary, Fosun Pharma, which has seen substantial investment with delayed returns [3] - The company intends to focus on its established industries, innovating within traditional sectors, such as the recent development of a new low-alcohol product in the liquor industry to cater to health-conscious consumers [3]